Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,447 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colon/Rectal Cancer Rectal Cancer Clear all

Conditions: Colorectal Cancer
Interventions: Branch I, Branch II, Branch III, Branch IV, Branch V; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 50 Years to 74 Years
Enrollment: 7,711 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Rectal Cancer, Ulcerative Colitis, Familial Adenomatous Polyposis, Diverticulitis
Interventions: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement, Staple line without reinforcement; Device · Procedure
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 16
States / cities: Mobile, Alabama • Los Angeles, California • Weston, Florida + 12 more

Conditions: Colorectal Cancer
Interventions: edrecolomab, sargramostim; Biological
Lead sponsor: James Ahlgren; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma
Interventions: Educational Intervention, Electronic Health Record Review, Follow-Up, Internet-Based Intervention, Interview, Survey Administration; Other · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Interventions: IOV-5001; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Neoplasms
Interventions: 1018 ISS immunostimulatory oligonucleotide; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
Interventions: fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more

Conditions: Neoplasms
Interventions: ADH300004; Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions: Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions: GRT-C903, GRT-R904, nivolumab, ipilimumab; Biological
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more

Conditions: Colorectal Cancer
Interventions: Capecitabine and Cetuximab; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Colorectal Carcinoma
Interventions: MGD007; Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more

Conditions: Colorectal Cancer
Interventions: Generic message, Tailored message; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
Interventions: TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab; Biological · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions: cediranib maleate, whole-brain radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions: PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl); Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Uterine Cancer
Interventions: Mindfulness Based Cancer Recovery; Behavioral
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III), Rectal Cancer (Stage III)
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,079 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo; Radiation · Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: irinotecan hydrochloride, semaxanib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: selumetinib, cetuximab, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Risk for Colorectal Cancer
Interventions: MUC1 - Poly ICLC; Biological
Lead sponsor: Robert Schoen; Other
Eligibility: 40 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more

Search by objective public record fields.

The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation

Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

A Study of IOV-5001 in Adults With Advanced Solid Tumors

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Tailored Messaging for CRC Screening

TCR1188-ABC Cells in KRAS-mutated Cancers

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy

Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation